Table 2 Baseline characteristics in trimmed cohort
Anti-TNF (n = 175) | Other bDMARD (n = 94) | |
|---|---|---|
Mean (± SD) or median (IQR) or % | ||
Age, years | 58 (±12) | 60 (±11) |
Female | 86% | 88% |
Disease duration, years | 12 (5, 26) | 19 (10, 30) |
Seropositive, RF or CCP | 79% | 85% |
DAS28-CRP at T0 | 4.0 (2.9, 5.3) | 4.4 (3.0, 5.4) |
DAS28-CRP at T1 | 3.4 (2.4, 4.7) | 3.9 (2.5, 5.2) |
Modified HAQ score at T0 | 0.4 (0.1, 0.6) | 0.6 (0.1, 1.0) |
Modified HAQ score at T1 | 0.3 (0, 0.8) | 0.5 (0.1, 0.8) |
Corticosteroid use | ||
Current | 41% | 57% |
In past 6 months | 58% | 79% |
Ever | 90% | 96% |
Cumulative glucocorticoid, mg | 2464 (336, 12156) | 6592 (1230, 17,546) |
Prior TNF use | 59% | 92% |
Concomitant non-biologic DMARD | 69% | 60% |
Cigarette use, pack-years | 0 (0, 13) | 2.3 (0, 14) |
Smoking status | ||
Never smoker | 51% | 47% |
Past smoker | 41% | 51% |
Current smoker | 8% | 2% |
Diabetes | 7% | 9% |